Temporal Trends in Antithrombotic Therapy for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention From 2014 to 2022 in Japan

Figures

• 

  Figure 1.. Guidelines and trials of antithrombotic therapy after percutaneous coronary intervention (PCI) and survey schedule. ACS, acute coronary syndrome; AF, atrial fibrillation; AHA, American Heart Association; CCS, chronic coronary syndrome; DAPT, dual antiplatelet therapy; JCS, Japanese Circulation Society; M, months; OAC, oral anticoagulant; TAT, triple antithrombotic therapy; W, weeks. Trials: AFIRE, Atrial Fibrillation and Ischemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease; AUGUSTUS, An Open-Label, 2×2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban Versus Vitamin K Antagonist and Aspirin Versus Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention; ENTRUST AF-PCI, Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation; PIONEER AF-PCI, Open-Label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects with Atrial Fibrillation who Undergo Percutaneous…

• 

  Figure 2.. (A) Estimated percentage of patients with atrial fibrillation (AF) or atrial flutter who undergo stent implantation (Question 1). (B) Frequency of bare-metal stent (BMS) implantation (Question 2). PCI, percutaneous coronary intervention.

• 

  Figure 3.. Choice of direct oral anticoagulant (DOAC) vs. warfarin for anticoagulant (Question 3).

• 

  Figure 4.. Duration of triple antithrombotic treatment in the case of (A) chronic coronary syndrome (CCS) or (B) acute coronary syndrome (ACS) plus drug-eluting stent (DES) implantation (Question 4).

• 

  Figure 5.. (A) Antiplatelet agent stopped first and (B) its timing (Questions 5 and 6). mo, months; P2Y12i, P2Y12 inhibitor.

• 

  Figure 6.. Preferred antithrombotic treatment strategy (Question 7). AC, anticoagulant; P2Y12i, P2Y12 inhibitor; TAT, triple antithrombotic therapy.